0
0
The Novavax vaccine NVX-CoV2373 is expected to receive its approval this week, according to the director general of public health. In a best-case scenario, that would make it available in Austria before the end of the year.
Austrians should not wait for inactivated vaccines
Katharina Reich, director general for public health, expects the new NVX-CoV2373 protein vaccine from U.S. pharmaceutical company Novavax to be approved in the coming days and, in a best-case scenario, delivered to Austria before the end of December.
“An additional vaccine will reach our portfolio very soon,” Reich says, referring to the U.S. vaccine, which is intended primarily to reach the vaccine-skeptical population.
Novavax neither mRNA nor vector vaccine
The Novavax product, unlike previously approved vaccines, is neither an mRNA vaccine – like the preparations from Biontech and Moderna – nor a vector vaccine like those from Astrazeneca and Johnson & Johnson. The vaccine contains tiny particles composed of a lab-created version of the spike protein of Sars-CoV-2.
Booster vaccine, omicron vaccine expected
Still, he said, it is important to get vaccinated or boostered now and not wait for the new vaccine. Seven million doses of vaccine are currently in storage in Austria.
Reich also expects an adapted Omicron vaccine. This would be added to the current vaccine doses and could be rolled out over the next year. However, immunization with first, second and booster doses should already provide basic immunization before the new variant.
This post has already been read 567 times!
